Prescient Therapeutics Ltd
PTX
Company Profile
Business description
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Contact
Sector
Healthcare
Stock type
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,561.70 | 142.70 | -1.85% |
| CAC 40 | 6,890.92 | 209.50 | -2.95% |
| DAX 40 | 19,740.47 | 539.79 | -2.66% |
| Dow JONES (US) | 37,634.57 | 11.02 | -0.03% |
| FTSE 100 | 7,688.55 | 221.98 | -2.81% |
| HKSE | 20,264.49 | 136.81 | 0.68% |
| NASDAQ | 15,471.87 | 203.96 | 1.34% |
| Nikkei 225 | 31,714.03 | 1,298.55 | -3.93% |
| NZX 50 Index | 11,806.55 | 84.89 | -0.71% |
| S&P 500 | 5,000.28 | 17.51 | 0.35% |
| S&P/ASX 200 | 7,375.00 | 135.00 | -1.80% |
| SSE Composite Index | 3,186.81 | 41.26 | 1.31% |